PIQ proteomics international laboratories ltd

0.00%

39.5¢

Excellent post & thanks @Khazar10. I don’t know why you waited...

First 27 Last

Share
Profile

Follow
Owl vs Fox

6,434 Posts.

5274

20/04/19

10:29

Post #: 38215461
Share

Originally posted by Khazar10: ↑

Hi all, I have not posted on the PIQ board as I only took a small parcel back in December after the collaboration with Janssen was announced.

However yesterday I have topped up significantly and the reason is the study results are impressive (we kinda knew it because study was stopped early, but i like to see results).

It is true that PIQ is not mentioned anywhere in the above article. This is not surprising because PIQ is still analysing the data from this study (see annoucement end of Jan, this will take till approximately June).

However the success of this study is extremely significant for PIQ.

One of the key sentences in the above article is :

"The landmark study evaluated the efficacy and safety of INVOKANA® versus placebo in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) when used in addition to standard of care."The key points here are that the study has been performed on patients that already suffer from CKD and T2D and that they drug is used in combination with standard of care.

This pretty much means that Janssen, one of the biggest pharma companies worldwide, will have a vast interest in identifying patients that are going to develop CKD in order to sell their drug as early as possible or even as a prophylactic combination therapy, massively increasing their target population. Of course, if the drug can actually work as a prophylactic drug has to be proved, possibly through post hoc analysis that is currently be conducted.

This means that Janssen itself will start to promote the use of promarkerD as a standard of care for T2D disease monitoring, something we already know works and is FDA approved.

Additionally and this is depending on the predictive capabilities that are currently tested, implement promarkerD as a Complementary Diagnostic (CDx) test for patient treated with this new groundbreaking drug.

This pretty much means that the success of this trial has significant implications for PIQ because one of the largest pharma companies worldwide will promote the test in order to increase their own sales, ultimately facilitating marked uptake of promarkerD.

The recent SP weakness hurt my small holding but was/is an amazing opportunity to top up because the success of this trial ensures that Janssen will be very interested in the success of PIQ.

Expand

Excellent post & thanks @Khazar10. I don’t know why you waited from Dec 18 to post here, but Welcome

The SLGT2 space is hotting up between Big Pharma competitors & extra indications, this has been going on now for a couple of years, Astra Zeneca, Boehringer/Eli Lilly, Johnson & Johnson/Janssen. A recent article FYI:

https://www.fiercepharma.com/pharma/jardiance-sales-boost-boehringer-ingelheim-s-revenue-2018

Being on the cutting edge of drug development & predictive testing is all important to Big Pharma in the difference of billions of dollars. Please don’t forget about PIQ’s recent ANN regarding the USA patent granted for biomarker in drug development in abnormal kidney function:

https://www.asx.com.au/asxpdf/20190221/pdf/442tgnzpnfvks0.pdf

We haven’t really discussed this much here & what this means for what is going on currently in the Diabetes/DKD space.

I hope everyone is having a great Easter.

PIQ Price at posting: 29.0¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

FTL

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

ASE

Astute delivers high-grade lithium hits at Red Mountain

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

RNU

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Most investors will get this earnings season wrong. Will you?

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

SGQ

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

First 27 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 39.5¢		Change 0.000(0.00%)		Mkt cap ! $64.65M

Open	High	Low	Value	Volume
39.0¢	40.0¢	38.0¢	$98.01K	252.5K

Buyers (Bids)

No.	Vol.	Price($)
1	9722	38.0¢

Sellers (Offers)

Price($)	Vol.	No.
39.5¢	44999	1

View Market Depth

No.	Vol.	Price($)
1	9722	0.380
1	1400	0.375
6	97160	0.370
1	10000	0.365
4	13174	0.360

Price($)	Vol.	No.
0.395	44999	1
0.400	14573	2
0.410	100000	1
0.420	10000	1
0.430	20000	1

Last trade - 16.10pm 25/07/2025 (20 minute delay)

PIQ (ASX) Chart

Excellent post & thanks @Khazar10. I don’t know why you waited...

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Astute delivers high-grade lithium hits at Red Mountain

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Most investors will get this earnings season wrong. Will you?

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Excellent post & thanks @Khazar10. I don’t know why you waited...

Top Stories

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Astute delivers high-grade lithium hits at Red Mountain

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Most investors will get this earnings season wrong. Will you?

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News